Connect with us

Hi, what are you looking for?

Jewish Business News


Teva launches generic migraine treatment

Teva is the first applicant to receive approval and will have market exclusivity for generic Axert until November.


Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has launched generic treatment is for migraine, Axert (almotriptan malate) tablets in 6.25 mg and 12.5 mg dosages, in the US.

Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert expires on November 7, 2015.

Teva continues to deliver on its generics business strategy and remains focused on increasing its first to file regulatory submissions in the US. With over 375 generic medicines available, Teva has the largest portfolio of safe, effective, US Food and Drug Administration (FDA) -approved generic products on the market.

Axert (almotriptan malate) tablets, marketed by Janssen Pharmaceuticals, had annual sales of approximately $31 million in the US, according to IMS data as of March 2015.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


Now Platika joins and elite club of $10 billion plus Israeli firms.